Wire · opportunities
Lupin Gets FDA Approval for Hyperkalemia Drug
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
The US Food and Drug Administration approved Lupin's drug Sodium Zirconium Cyclosilicate for oral suspension to treat hyperkalemia, establishing it as a bioequivalent to AstraZeneca's Lokelma. The drug's estimated annual US sales are $568 million.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face new competition in hyperkalemia treatment as Lupin's FDA approval opens the door to a biosimilar alternative to AstraZeneca's Lokelma. Prepare to respond to pricing and market share shifts in this $568 million US drug segment.
◆ Coverage
1 source · 10 Aug 2026
◆ Related on Wire
◆ Topics
Biotechfda-approvalhyperkalemiabiosimilardrug-launchlupin